Weekly Analysts’ Ratings Updates for WAVE Life Sciences (WVE)

A number of research firms have changed their ratings and price targets for WAVE Life Sciences (NASDAQ: WVE):

• 1/3/2026 – WAVE Life Sciences was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 12/19/2025 – WAVE Life Sciences had its price target raised by analysts at HC Wainwright from $22.00 to $30.00. They now have a “buy” rating on the stock.
• 12/16/2025 – WAVE Life Sciences was given a new $32.00 price target on by analysts at UBS Group AG.
• 12/16/2025 – WAVE Life Sciences had its price target raised by analysts at Oppenheimer Holdings, Inc. from $24.00 to $32.00. They now have an “outperform” rating on the stock.
• 12/15/2025 – WAVE Life Sciences had its price target raised by analysts at Truist Financial Corporation from $36.00 to $50.00. They now have a “buy” rating on the stock.
• 12/13/2025 – WAVE Life Sciences was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/12/2025 – WAVE Life Sciences had its price target raised by analysts at B. Riley from $19.00 to $37.00. They now have a “buy” rating on the stock.
• 12/12/2025 – WAVE Life Sciences had its price target raised by analysts at Wedbush from $20.00 to $33.00. They now have an “outperform” rating on the stock.
• 12/9/2025 – WAVE Life Sciences had its price target raised by analysts at Wells Fargo & Company from $16.00 to $29.00. They now have an “overweight” rating on the stock.
• 12/9/2025 – WAVE Life Sciences was given a new $30.00 price target on by analysts at UBS Group AG.
• 12/9/2025 – WAVE Life Sciences had its price target raised by analysts at Citigroup Inc. from $16.00 to $30.00. They now have a “buy” rating on the stock.
• 12/9/2025 – WAVE Life Sciences had its price target raised by analysts at Cantor Fitzgerald from $12.00 to $34.00. They now have an “overweight” rating on the stock.
• 12/8/2025 – WAVE Life Sciences was upgraded by analysts at Royal Bank Of Canada from a “sector perform” rating to an “outperform” rating. They now have a $27.00 price target on the stock, up previously from $9.00.
• 12/8/2025 – WAVE Life Sciences had its “outperform” rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $21.00 price target on the stock.
• 12/8/2025 – WAVE Life Sciences had its price target raised by analysts at Canaccord Genuity Group Inc. from $19.00 to $40.00. They now have a “buy” rating on the stock.
• 12/8/2025 – WAVE Life Sciences was given a new $28.00 price target on by analysts at Morgan Stanley.
• 12/8/2025 – WAVE Life Sciences had its “outperform” rating reaffirmed by analysts at Leerink Partners.
• 11/11/2025 – WAVE Life Sciences had its price target raised by analysts at Wedbush from $18.00 to $20.00. They now have an “outperform” rating on the stock.
• 11/11/2025 – WAVE Life Sciences had its price target lowered by analysts at Wells Fargo & Company from $18.00 to $16.00. They now have an “overweight” rating on the stock.

Insiders Place Their Bets

In other news, CFO Kyle Moran sold 50,036 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $20.03, for a total value of $1,002,221.08. Following the completion of the sale, the chief financial officer directly owned 89,218 shares in the company, valued at $1,787,036.54. The trade was a 35.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Gregory L. Verdine sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $13.47, for a total value of $269,400.00. Following the transaction, the director directly owned 275,217 shares of the company’s stock, valued at approximately $3,707,172.99. The trade was a 6.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 902,742 shares of company stock worth $13,313,763. Corporate insiders own 23.98% of the company’s stock.

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.